Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Esperas Pharma Inc.
Cyteir Therapeutics, Inc.
Eli Lilly and Company
Kyowa Kirin Co., Ltd.
GlaxoSmithKline
Altor BioScience
Genentech, Inc.
Henry M. Jackson Foundation for the Advancement of Military Medicine
Hellenic Oncology Research Group